FR EA

Extract to table

Pull the structured facts out of a document: parties, dates, amounts, obligations.

Extract to table / responses-to-vantage-interrogatories.docx
responses-to-vantage-interrogatories.docx · 1018-00007

Parties

INTERROGATORIES Plaintiff Penterra Pharmaceuticals Corp
Harkness LLP
Penterra Pharmaceuticals Corp
See Cambridge Biotech Corp
M. Rourke
Polk LLP
Commercial Operations Penterra Pharmaceuticals Corp
Plaintiff Penterra Pharmaceuticals Corp

Dates

September 3, 2021
September 17, 2021
July 1, 2017
January 12, 2018
June 15, 2021
February 15, 2021
March 22, 2021
September 14, 2020
March 8, 2021
March 29, 2021

Amounts

$35
$11.2
$14.8
$18.3
$16.1
$21.47
$9.5

Obligations

No response or objection herein shall be construed as a representation that Penterra's investigation into the facts and circumstances underlying this litigation is complete
The provision of any response herein shall not constitute a waiver of any objection stated or reserved, nor shall it constitute an admission that the information provided is relevant or admissible
No response, partial response, or inadvertent production herein shall be deemed or construed as a waiver, in whole or in part, of any such privilege, immunity, or protection
3 of the EDA provides that Vantage "shall not distribute the Products outside the Territory without the prior written consent of [Penterra]
1 of the EDA provides: "No amendment, modification, or waiver of any provision of this Agreement shall be effective unless set forth in a written instrument signed by both parties
1 of the EDA provides, in relevant part: "No amendment, modification, or waiver of any provision of this Agreement shall be effective unless set forth in a written instrument signed by both parties